|
|
| (4 intermediate revisions not shown.) |
| Line 1: |
Line 1: |
| - | ==GLOBAL STRUCTURE AND DYNAMICS OF HUMAN APOLIPOPROTEIN CII IN COMPLEX WITH MICELLES: EVIDENCE FOR INCREASED MOBILITY OF THE HELIX INVOLVVED IN THE ACTIVATION OF LIPOPROTEIN LIPASE.== | + | |
| - | <StructureSection load='1o8t' size='340' side='right' caption='[[1o8t]], [[NMR_Ensembles_of_Models | 68 NMR models]]' scene=''> | + | ==Global Structure and Dynamics of Human Apolipoprotein CII in Complex with Micelles: Evidence for increased mobility of the helix involved in the activation of lipoprotein lipase== |
| | + | <StructureSection load='1o8t' size='340' side='right'caption='[[1o8t]]' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[1o8t]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1O8T OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1O8T FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[1o8t]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1O8T OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=1O8T FirstGlance]. <br> |
| - | </td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1by6|1by6]], [[1i5j|1i5j]]</td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Solution NMR</td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1o8t FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1o8t OCA], [http://pdbe.org/1o8t PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=1o8t RCSB], [http://www.ebi.ac.uk/pdbsum/1o8t PDBsum]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=1o8t FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1o8t OCA], [https://pdbe.org/1o8t PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=1o8t RCSB], [https://www.ebi.ac.uk/pdbsum/1o8t PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=1o8t ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | + | == Disease == |
| | + | [https://www.uniprot.org/uniprot/APOC2_HUMAN APOC2_HUMAN] Defects in APOC2 are the cause of hyperlipoproteinemia type 1B (HLPP1B) [MIM:[https://omim.org/entry/207750 207750]. It is an autosomal recessive trait characterized by hypertriglyceridemia, xanthomas, and increased risk of pancreatitis and early atherosclerosis.<ref>PMID:8323539</ref> |
| | == Function == | | == Function == |
| - | [[http://www.uniprot.org/uniprot/APC2_HUMAN APC2_HUMAN]] Promotes rapid degradation of CTNNB1 and may function as a tumor suppressor. May function in Wnt signaling.<ref>PMID:9823329</ref> <ref>PMID:10021369</ref> <ref>PMID:11691822</ref> | + | [https://www.uniprot.org/uniprot/APOC2_HUMAN APOC2_HUMAN] Component of the very low density lipoprotein (VLDL) fraction in plasma, and is an activator of several triacylglycerol lipases. The association of APOC2 with plasma chylomicrons, VLDL, and HDL is reversible, a function of the secretion and catabolism of triglyceride-rich lipoproteins, and changes rapidly. |
| | == Evolutionary Conservation == | | == Evolutionary Conservation == |
| | [[Image:Consurf_key_small.gif|200px|right]] | | [[Image:Consurf_key_small.gif|200px|right]] |
| | Check<jmol> | | Check<jmol> |
| | <jmolCheckbox> | | <jmolCheckbox> |
| - | <scriptWhenChecked>select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/o8/1o8t_consurf.spt"</scriptWhenChecked> | + | <scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/o8/1o8t_consurf.spt"</scriptWhenChecked> |
| | <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked> | | <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked> |
| | <text>to colour the structure by Evolutionary Conservation</text> | | <text>to colour the structure by Evolutionary Conservation</text> |
| Line 31: |
Line 34: |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Human]] | + | [[Category: Homo sapiens]] |
| - | [[Category: Lycksell, P O]] | + | [[Category: Large Structures]] |
| - | [[Category: Martinez, G V]] | + | [[Category: Lycksell PO]] |
| - | [[Category: Nilsson, S]] | + | [[Category: Martinez GV]] |
| - | [[Category: Olivecrona, G]] | + | [[Category: Nilsson S]] |
| - | [[Category: Schleucher, J]] | + | [[Category: Olivecrona G]] |
| - | [[Category: Shen, Y]] | + | [[Category: Schleucher J]] |
| - | [[Category: Wijmenga, S]] | + | [[Category: Shen Y]] |
| - | [[Category: Yin, Y]] | + | [[Category: Wijmenga S]] |
| - | [[Category: Zdunek, J]] | + | [[Category: Yin Y]] |
| - | [[Category: Activation mechanism]]
| + | [[Category: Zdunek J]] |
| - | [[Category: Apocii]]
| + | |
| - | [[Category: Chylomicron]]
| + | |
| - | [[Category: Domain motion]]
| + | |
| - | [[Category: Dynamic]]
| + | |
| - | [[Category: Global structure]]
| + | |
| - | [[Category: Helix]]
| + | |
| - | [[Category: Lipid degradation]]
| + | |
| - | [[Category: Lipid transport]]
| + | |
| - | [[Category: Local structure]]
| + | |
| - | [[Category: Lpl]]
| + | |
| - | [[Category: Micelle]]
| + | |
| - | [[Category: Sd]]
| + | |
| Structural highlights
Disease
APOC2_HUMAN Defects in APOC2 are the cause of hyperlipoproteinemia type 1B (HLPP1B) [MIM:207750. It is an autosomal recessive trait characterized by hypertriglyceridemia, xanthomas, and increased risk of pancreatitis and early atherosclerosis.[1]
Function
APOC2_HUMAN Component of the very low density lipoprotein (VLDL) fraction in plasma, and is an activator of several triacylglycerol lipases. The association of APOC2 with plasma chylomicrons, VLDL, and HDL is reversible, a function of the secretion and catabolism of triglyceride-rich lipoproteins, and changes rapidly.
Evolutionary Conservation
Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf.
Publication Abstract from PubMed
Apolipoprotein CII (apoCII), a surface constituent of plasma lipoproteins, is the activator for lipoprotein lipase (LPL) and is therefore central for lipid transport in blood. The three-dimensional structure of (13)C-, (15)N-enriched human full-length apoCII in complex with sodium dodecyl sulfate (SDS) micelles is reported. In addition to the structure determination, (15)N-relaxation measurements have been performed at two magnetic fields to characterize the dynamics of the backbone of apoCII in the complex. The relaxation data also provided global structural constraints, viz. the orientation of helices in the complex. In addition, global constraints were derived from the fact that apoCII helices are attached to the surface of the SDS micelle and that the hydrophobic moments of each helix faces the interior of the micelle. These three categories of global constraints, together with the local classical NMR constraints, were sufficient to define the 3D structure of the apoCII-SDS micelle complex. To our knowledge, this presents the first example in which the global structure of a protein-SDS micelle complex has been determined. The C-terminal helix of apoCII is known to be responsible for the activation of LPL. This helix is distinguished from the other helices by a higher degree of internal motion on the nanosecond time scale as shown by the relaxation data. The overall structure and the internal dynamics, combined with previous mutation data, give important clues toward a possible mechanism for the activation of LPL by apoCII.
Global structure and dynamics of human apolipoprotein CII in complex with micelles: evidence for increased mobility of the helix involved in the activation of lipoprotein lipase.,Zdunek J, Martinez GV, Schleucher J, Lycksell PO, Yin Y, Nilsson S, Shen Y, Olivecrona G, Wijmenga S Biochemistry. 2003 Feb 25;42(7):1872-89. PMID:12590574[2]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Inadera H, Hibino A, Kobayashi J, Kanzaki T, Shirai K, Yukawa S, Saito Y, Yoshida S. A missense mutation (Trp 26-->Arg) in exon 3 of the apolipoprotein CII gene in a patient with apolipoprotein CII deficiency (apo CII-Wakayama). Biochem Biophys Res Commun. 1993 Jun 30;193(3):1174-83. PMID:8323539 doi:http://dx.doi.org/S0006-291X(83)71749-3
- ↑ Zdunek J, Martinez GV, Schleucher J, Lycksell PO, Yin Y, Nilsson S, Shen Y, Olivecrona G, Wijmenga S. Global structure and dynamics of human apolipoprotein CII in complex with micelles: evidence for increased mobility of the helix involved in the activation of lipoprotein lipase. Biochemistry. 2003 Feb 25;42(7):1872-89. PMID:12590574 doi:http://dx.doi.org/10.1021/bi0267184
|
